Search research articles
Contact Us
Filters
Showing results (1-10 of 45) with videos related to
Page
of 5
Sort By:
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
September 6, 2024
Clinical decision making around commercial use of gene and genetic therapies for spinal muscular atrophy
Megan A Waldrop
Neurologic Clinics
|
July 25, 2020
Spinal Muscular Atrophy in the Treatment Era
Megan A Waldrop, Bakri H Elsheikh
Pediatric Pulmonology
|
September 5, 2020
Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy
Nicolas J Abreu, Megan A Waldrop
Current Treatment Options in Neurology
|
May 1, 2019
Current Treatment Options in Neurology-SMA Therapeutics
Megan A Waldrop, Stephen J Kolb
Current Opinion in Neurology
|
July 26, 2019
Update in Duchenne and Becker muscular dystrophy
Megan A Waldrop, Kevin M Flanigan
Seminars in Pediatric Neurology
|
April 24, 2021
Spinal Muscular Atrophy
Stefan Nicolau, Megan A Waldrop, Anne M Connolly, et al.
Muscle & Nerve
|
May 7, 2021
Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy
Bo Hoon Lee, Megan A Waldrop, Anne M Connolly, et al.
Annals of Neurology
|
February 15, 2020
The Genotypic and Phenotypic Spectrum of BICD2 Variants in Spinal Muscular Atrophy
Daniel C Koboldt, Megan A Waldrop, Richard K Wilson, et al.
Endocrinology
|
June 23, 2007
Release of glutamate decarboxylase-65 into the circulation by injured pancreatic islet beta-cells
Megan A Waldrop, Arthur T Suckow, Santica M Marcovina, et al.
Pediatric Neurology
|
July 6, 2017
Clinicopathologic Conference: A Newborn With Hypotonia, Cleft Palate, Micrognathia, and Bilateral Club Feet
Megan A Waldrop, Daniel R Boue, Emily Sites, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 45) with videos related to
Sort By:
Page
of 5
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
September 6, 2024
Clinical decision making around commercial use of gene and genetic therapies for spinal muscular atrophy
Megan A Waldrop
Neurologic Clinics
|
July 25, 2020
Spinal Muscular Atrophy in the Treatment Era
Megan A Waldrop, Bakri H Elsheikh
Pediatric Pulmonology
|
September 5, 2020
Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy
Nicolas J Abreu, Megan A Waldrop
Current Treatment Options in Neurology
|
May 1, 2019
Current Treatment Options in Neurology-SMA Therapeutics
Megan A Waldrop, Stephen J Kolb
Current Opinion in Neurology
|
July 26, 2019
Update in Duchenne and Becker muscular dystrophy
Megan A Waldrop, Kevin M Flanigan
Seminars in Pediatric Neurology
|
April 24, 2021
Spinal Muscular Atrophy
Stefan Nicolau, Megan A Waldrop, Anne M Connolly, et al.
Muscle & Nerve
|
May 7, 2021
Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy
Bo Hoon Lee, Megan A Waldrop, Anne M Connolly, et al.
Annals of Neurology
|
February 15, 2020
The Genotypic and Phenotypic Spectrum of BICD2 Variants in Spinal Muscular Atrophy
Daniel C Koboldt, Megan A Waldrop, Richard K Wilson, et al.
Endocrinology
|
June 23, 2007
Release of glutamate decarboxylase-65 into the circulation by injured pancreatic islet beta-cells
Megan A Waldrop, Arthur T Suckow, Santica M Marcovina, et al.
Pediatric Neurology
|
July 6, 2017
Clinicopathologic Conference: A Newborn With Hypotonia, Cleft Palate, Micrognathia, and Bilateral Club Feet
Megan A Waldrop, Daniel R Boue, Emily Sites, et al.
Page
of 5